Clinical trial
Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in…
NCT00123487 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00123487 |
|---|---|
| Title | Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML |
| Official title | A Randomized Two-Arm, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 70 mg Twice Daily or 140 mg Once Daily in Subjects With Chronic Myeloid Leukemia in Accelerated Phase or in Myeloid or Lymphoid Blast Phase or With Philadelphia Chromosome Positive Acute… |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Myeloid Leukemia, Chronic, Accelerated Phase, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive |
| Intervention type | Drug |
| Interventions | dasatinib |
| Enrollment | 638 |
| Start date | Jun 1, 2005 |
| Primary completion | Nov 1, 2006 |
| Completion | Jun 1, 2013 |
| First posted | Jul 25, 2005 |
| Last update posted | Nov 3, 2014 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, Finland, France, Germany, Greece and 20 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: